ALZHEIMER?S DISEASE RESEARCH CENTER

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 目的：探讨在阿尔茨海默病患者无临床症状阶段(临床前期)预防阿尔茨海默病的新的诊断试验和潜在治疗方法。 老年医学和老年学教授、老年研究、教育和临床中心(GRECC)主任桑杰·阿萨纳在2009年5月获得了一笔为期5年的690万美元的国家老龄研究所赠款，以启动威斯康星州阿尔茨海默病研究中心(ADRC)。 这个新的中心将建立在威斯康星大学麦迪逊分校卓越的神经科学研究的优势之上，提供阿尔茨海默病(AD)和相关疾病的最先进的资源、基础设施和专业知识。该中心主要关注阿尔茨海默病的临床前和早期诊断和进展，将扩大威斯康星州阿尔茨海默氏症预防注册中心的科学目标，并显著加强对遭受阿尔茨海默病蹂躏的威斯康星州居民的护理。 ADRC将由六个核心组成：行政、临床、数据管理和生物统计学、神经病理学和生物标记物、教育和转移以及少数族裔招募卫星计划。该中心将以威斯康星州大学在阿尔茨海默病非常成功的研究计划和最近几项趋同的发展为基础：其中包括威斯康星州大学领导层对AD研究的新重点、UW大学对AD研究的重大机构和州财政承诺、UW大学在神经科学方面的几个知名项目、UW大学出色的临床项目、覆盖全州的广泛的痴呆症诊断诊所网络、通过少数族裔招募卫星计划(MRSP)接触少数族裔、低收入和农村人口、承认几位UW大学研究员在AD研究中的地位，以及UW大学众多中心和机构在老龄化和神经科学研究方面的密切合作。 参与的中心和研究所包括威斯康星州阿尔茨海默氏症研究所、老龄研究所、威斯康星州韦斯曼中心、威斯康星州韦斯曼脑成像和行为实验室、NIH/CTSA资助的临床和翻译研究所(ICTR)、威斯康星州国家灵长类动物研究中心、生物技术中心、基因组中心、临床和翻译研究核心(前身为UW GCRC)和麦迪逊退伍军人事务部(VA)老年研究、教育和临床中心(GRECC)。鉴于能够获得杰出的资源和专业知识，威斯康星州ADRC已做好准备，为AD研究领域做出新的贡献，并为遭受疾病破坏的患者提供出色的临床护理。 威斯康星州ADRC的主要重点是确定新的诊断测试和潜在的治疗方法，以在患者没有临床症状的阶段(临床前阶段)预防阿尔茨海默病。阿萨纳的团队预计，这种疗法将有助于减少阿尔茨海默病患者的数量。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Objective: To identify novel diagnostic tests and potential therapies for the prevention of Alzheimer's disease at a stage when patients have no clinical symptoms (preclinical stage). Sanjay Asthana, professor of geriatrics and gerontology, and director of the Geriatric Research, Education and Clinical Center (GRECC), in May 2009 landed a five-year $6.9 million National Institutes on Aging grant to launch the Wisconsin Alzheimer's Disease Research Center (ADRC). This new center will build upon the strengths of UW-Madison's remarkable neuroscience research to provide state-of-the-art resources, infrastructure, and expertise in Alzheimer's disease (AD) and related illnesses. With the major focus on preclinical and early diagnosis and progression of AD, the center will expand the scientific objectives of the Wisconsin Registry for Alzheimer's Prevention and significantly enhance care of Wisconsin residents suffering from the devastations of AD. The ADRC will be comprised of six cores: Administrative, Clinical, Data Management and Biostatistics, Neuropathology and Biomarkers, Education and Transfer and the Minority Recruitment Satellite Program. The center will build upon the highly successful UW research program in AD and several recent convergent developments: These include a new focus of the UW leadership on AD, substantial institutional and state financial commitment to AD research, presence of several renowned programs in neuroscience on the UW campus, outstanding UW clinical programs, an extensive statewide network of dementia diagnostic clinics, access to minority, low-income and rural populations through the Minority Recruitment Satellite Program (MRSP), acknowledged status of several UW investigators in AD research, and close collaborations between numerous UW centers and institutes in aging and neuroscience research. The involved centers and institutes include the Wisconsin Alzheimer's Institute, Institute on Aging, UW Waisman Center, UW Waisman Laboratory for Brain Imaging and Behavior, NIH/CTSA-funded Institute for Clinical and Translational Research (ICTR), Wisconsin National Primate Research Center, Biotechnology Center, Genome Center, Clinical and Translational Research Core (formerly known as the UW GCRC), and Madison Veterans Affairs (VA) Geriatric Research, Education and Clinical Center (GRECC). Given the access to outstanding resources and expertise, the Wisconsin ADRC is well poised to make novel contributions to the field of AD research and provide outstanding clinical care to patients suffering from the devastations of the disease. The major focus of the Wisconsin ADRC is to identify novel diagnostic tests and potential therapies for the prevention of Alzheimer's disease at a stage when patients have no clinical symptoms (preclinical stage). Asthana's team anticipates that such therapies will help reduce the number of individuals suffering from Alzheimer's disease.